Combining Cannabinoids with Radiotherapy Improves Cancer Outcomes

Cannabis Science Inc. has announced the second publication of its research results on the use of cannabinoids to treat various cancers. The peer-reviewed research article, “Enhancing the Therapeutic Efficacy of Cancer Treatment with Cannabinoids”, was published on April 24thin Frontiers in Oncology.

The article can be viewed at https://www.frontiersin.org/articles/10.3389/fonc.2018.00114/full.

Cannabis Science’s latest article explores the potential of combination approaches employing cannabinoids with radiotherapy and smart biomaterials toward enhancing therapeutic efficacy during treatment of pancreatic and lung cancers.

"This second publication reflects our ongoing work and we continue to examine the effect of cannabinoids with and without radiation therapy on lung and pancreatic cancer. This work will form part of our applications to the U.S. Food and Drug Administration (FDA). As we continue this work we will expand our pharmaceutical development program from farm to bedside," stated Dr. Allen A. Herman, Cannabis Science’s Chief Medical Officer (CMO).

You can learn about the best cannabis extraction methods for marijuana concentrates here. 

The innovative drug delivery strategy for cannabinoids is consistent with the three primary elements in Cannabis Science's drug development program: (1) Defining the effectiveness and specificity of CBDs being tested; (2) Identifying and testing drug delivery mechanisms; and (3) Testing and evaluating the impact of co-interventions, and the application of additional diagnostic and/or therapeutic procedures to participants in randomized controlled trials. The company's initial results point to the importance of drug delivery systems and the impact of co-interventions.

The initial results of their current research were published in September 2017 in Frontiers in Oncology. This peer-reviewed article, “Nanoparticle Drones to Target Lung Cancer with Radiosensitizers and Cannabinoids”, has been viewed more than 11,000 times, and has more views than 96% of all Frontiers’ articles. The first article addresses drug delivery and highlights an innovative strategy to transport cannabinoids directly to cancer cells with minimal toxicities or side effects that have so far hampered clinical translation efforts.

To view Cannabis Science’s first article in Frontiers in Oncology:

https://www.frontiersin.org/articles/10.3389/fonc.2017.00208/full

 “This strong – and increasing – level of interest by our colleagues validates the importance of our research,” stated Mr. Raymond C. Dabney, Cannabis Science’s President, Chief Executive Officer, and Co-founder. “We believe that our Company, along with our collaborators, are helping to better understand the science of cannabinoid utilization in cancer therapeutics and novel ways of drug delivery and targeting. In so doing, we expect to develop medicines that can positively impact so many patients in the U.S. and worldwide.”

Cannabis Science’s research forms part of a pipeline from research to scientific publication that the Company is developing with its research partners, and demonstrates the Company’s strong commitment to science in its pharmaceutical development program. “We developed this pipeline to ensure that Cannabis Science’s research work reaches the scientific community and the public in a timely fashion,” stated Mr. Dabney. 

Cannabis Science’s funded research currently focuses on the clinical applications of CBDs in cancer treatment and pain management. The Company’s research will expand to investigate the effectiveness of CBD treatment in an increasing array of cancers, especially difficult to treat cancers and those with high fatality rates; develop novel targeted delivery methods in the use of CBDs, and – with advances in bioinformatics, computer science, and pharmacology – explore the mechanisms of action of CBDs in the management of disease.

This article has been republished from materials provided by Cannabis Science. Note: material may have been edited for length and content. For further information, please contact the cited source.